关于我们
上海镔铁生物科技有限责任公司
上海镔铁生物科技有限责任公司是一家临床阶段的生物医药科技创新企业。公司主要产品是靶向实体瘤的新型免疫细胞制剂。公司创始人在肿瘤免疫领域具有国际影响力，在美国原创开发的多个免疫治疗药物已进入临床试验阶段。
公司的长期目标是发展一系列治疗胰腺癌等复发难治恶性肿瘤的TCR产品，识别共享基因突变和肿瘤新生抗原，将细胞治疗产品做到个性化与通用相结合，缩短细胞治疗产品制备周期，提高细胞治疗的有效性和可及性。
Shanghai Bintie Biotechnology Co., Ltd. is a cutting-edge clinical-stage biotech company leading the way in developing a new type of immunocyte preparation that specifically targets solid tumors. The company's founder commands international influence in the field of tumor immunology, with several immunotherapy drugs, originally developed in the United States, currently in the clinical trial stage.
The company's unwavering long-term objective is to spearhead the development of a pioneering series of TCR products to effectively address recurrent and refractory malignant tumors, such as pancreatic cancer. Our mission encompasses the identification of TCRs that recognize shared cancer driver gene mutations and tumor neoantigens, the integration of personalized and universal cell therapy products, as well as the streamlining of the preparation cycle of cell therapy products, all with the ultimate goal of enhancing the effectiveness and accessibility of cell therapy.
镔铁生物愿景
以临床需求为中心,为患者提供价值为导向
靶向KRAS突变为突破口,攻破难治实体瘤
建立有国际竞争力的创新型细胞治疗企业
Centered on medical needs and oriented by patient values
Targeting mutant KRAS as a breakthrough point to tackle refractory solid tumors,
